FLT3 and acute myeloid leukemia: Candidatecompound 34f showed high antiproliferative efficacy inthe FLT3-ITD-positive AML cell lines MV4-11 and MOLM-13 (7 and 9 nM,respectively) as well as in the MOLM-13 variant bearing the FLT3-ITD-D835Ymutation (4 nM) in comparison with low sensitivity of FLT3-independentcell lines, proving the FLT3-dependent mechanism of action.